PIER trial: Neoadjuvant therapy with panitumumab (P) and mFOLFOX-6 in an enriched population of patients with T3 rectal adenocarcinoma of the middle third with clear mesorectal fascia.

Carlos Fernández-Martos, Ruth Vera, Juan Ramón Ayuso et al.|Journal of Clinical Oncology|2018

Cited by 0